KM Research Hub
← 返回论文库
待处理 入排:符合 图源:待检查 入排置信度 0.96

Intismeran Autogene plus Pembrolizumab for Resected Stage IIB to IV Melanoma.

Georgina V Long, Muhammad A Khattak, Helen J Gogas, Dirk Schadendorf, Ana Arance, Matteo S Carlino, Piotr Rutkowski, Gareth Rivalland, Antoni Ribas, Janice M Mehnert, Patrick A Ott, Reinhard Dummer, Paola Queirolo, Christoffer Gebhardt, Caroline Dutriaux, Carlos Rojas, Yuanbin Chen, Lisa M Tachiki, Ronnie Shapira-Frommer, Oliver Bechter, Ryan J Sullivan, Alexander M M Eggermont, Laureen S Ojalvo, Michelle Brown, Jinchun Zhang, Dmitri O Grebennik, Mizuho Fukunaga-Kalabis, Paolo A Ascierto, Michele Del Vecchio, INTerpath-001 Investigators

N Engl J Med 10.1056/NEJMoa2609762

PMID43013837
PMCID-
DOI10.1056/NEJMoa2609762
发表日期2026-11-11
入排依据:明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
摘要

摘要

BACKGROUND: Intismeran autogene (intismeran) is an individualized neoantigen therapy that is designed to induce new T-cell responses and expand preexisting T-cell responses against patient-specific tumor neoantigens, which may potentially improve the efficacy of adjuvant therapy in patients with melanoma. METHODS: In this phase 3, double-blind trial, we randomly assigned patients with completely resected stage IIB to IV cutaneous melanoma in a 2:1 ratio to receive intramuscular intismeran (at a dose of 1 mg) or placebo every 3 weeks for nine doses; all the patients received intravenous pembrolizumab (at a dose of 400 mg) every 6 weeks for nine cycles. The primary end point was investigator-determined recurrence-free survival, assessed in a time-to-event analysis. Key secondary end points included investigator-determined distant-metastasis-free survival (assessed in a time-to-event analysis) and safety. RESULTS: A total of 1137 patients underwent randomization: 757 to the intismeran-pembrolizumab group and 380 to the placebo-pembrolizumab group. The median follow-up was 24.6 months. Recurrence-free survival at 24 months was 82.2% in the intismeran-pembrolizumab group and 70.0% in the placebo-pembrolizumab group (two-sided P<0.001); the piecewise hazard ratio was 0.99 (95% confidence interval [CI], 0.66 to 1.49) before 6 months and 0.42 (95% CI, 0.30 to 0.58) after 6 months. Distant-metastasis-free survival at 24 months was 88.5% with intismeran-pembrolizumab and 80.2% with placebo-pembrolizumab (two-sided P = 0.002); the piecewise hazard ratio was 1.01 (95% CI, 0.58 to 1.79) before 6 months and 0.50 (95% CI, 0.34 to 0.73) after 6 months. Adverse events of grade 3 or higher occurred in 23.6% of the patients in the intismeran-pembrolizumab group and 20.3% of the patients in the placebo-pembrolizumab group. Eight patients (1.1%) in the intismeran-pembrolizumab group died from an adverse event; five of the deaths occurred before intismeran was administered. CONCLUSIONS: Adjuvant therapy with intismeran plus pembrolizumab significantly prolonged recurrence-free survival and distant-metastasis-free survival as compared with pembrolizumab alone in patients with completely resected, high-risk cutaneous melanoma. (Funded by Merck Sharp and Dohme and Moderna; ClinicalTrials.gov number, NCT05933577.).

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。